Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology ...

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat ...

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a ...

It will fund validation awards to bring therapies to human trials and innovation awards to those that "push the boundaries" ...

The firm said it would focus resources on other late-stage programs after a Phase III study showed little survival benefit on first-line bemarituzumab.

The firm is expecting a preliminary data read out from the trial, which is already underway in the US, in the second half of this year.

Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle ...

EGFR drug ALX2004 and evorpacept, which recently showed activity with Jazz's Ziihera in CD47- and HER2-positive breast cancer.

The agency previously declined to approve the application for UX111, citing issues related to chemistry, manufacturing, and controls (CMC).

The company, founded by UC Berkeley scientists including Jennifer Doudna, is preparing to test its lead candidate STX-1150 in ...

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of ...

After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a ...